Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma to Alopecia

One-Sentence Summary

Bimatoprost is a synthetic prostamide F2α analog, internationally marketed as Lumigan® (intraocular pressure reduction in glaucoma) and Latisse® (FDA-approved for eyelash hypotrichosis), though it currently has no Taiwan regulatory authorization. The TxGNN model predicts it may be effective for Alopecia (including androgenetic alopecia and alopecia areata), with 11 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Glaucoma / Ocular hypertension (Lumigan®); Eyelash hypotrichosis (Latisse®, FDA-approved 2008)
Predicted New Indication	Alopecia (androgenetic alopecia and alopecia areata)
TxGNN Prediction Score	99.99%
Evidence Level	L2
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bimatoprost is a synthetic analog of prostaglandin F2α (prostamide class), primarily used in ophthalmology to lower intraocular pressure. Detailed MOA documentation for the Taiwan regulatory dossier is currently unavailable (DG002), but the mechanism underlying the alopecia prediction is well-characterized in the literature: bimatoprost binds FP receptors (prostaglandin F2α receptors) expressed in hair follicle dermal papilla cells, prolongs the anagen (active growth) phase of the hair cycle, and stimulates follicular cell proliferation. The biological plausibility of this application was first established when clinicians observed hypertrichosis as a side effect of topical prostaglandin analogs in glaucoma patients — an observation that directly led to FDA approval of Latisse®.

The bridge from eyelash hypotrichosis to scalp alopecia is mechanistically direct: the same FP receptor system present in eyelid follicles is expressed in scalp hair follicles. A landmark FASEB Journal study (PMID 23104985) demonstrated that prostamide-mediated signaling is functionally active in human scalp follicles and proposed bimatoprost as a candidate for scalp alopecias. Both androgenetic alopecia and alopecia areata are characterized by premature truncation of the anagen phase, making them logical targets for anagen-prolonging therapy.

Among the 10 TxGNN-predicted indications in this Evidence Pack, “alopecia” stands out as the sole indication with L2-grade clinical evidence. The remaining nine predictions — including rare malformation syndromes and genetic hair shaft disorders — are either biologically implausible links or have zero supporting clinical data (all rated L5/Hold). The high TxGNN scores for those conditions likely reflect non-specific prostaglandin–inflammation graph connections in the knowledge graph rather than genuine therapeutic opportunities.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01325337	Phase 2	Completed	307	Double-blind dose-comparison of bimatoprost vs. vehicle vs. open-label minoxidil 5% in male AGA — largest scalp AGA RCT for this drug
NCT01325350	Phase 2	Completed	306	Double-blind dose-comparison of bimatoprost vs. vehicle vs. open-label minoxidil 2% in female pattern hair loss
NCT01904721	Phase 2	Completed	244	Safety and efficacy of bimatoprost in male AGA — independent Phase 2 confirmatory study
NCT05600673	Phase 1/2	Completed	30	CO₂ fractional laser combined with bimatoprost 0.03% in alopecia areata — evaluates synergistic combination approach
NCT02170662	Phase 2	Completed	33	Mechanistic study of bimatoprost effect on androgen-dependent hair follicles — validates FP receptor pathway in scalp
NCT01023841	Phase 4	Completed	71	Bimatoprost 0.03% for eyelash hypotrichosis in children — provides pediatric safety profile
NCT02848300	Phase 1	Completed	11	Scalp pharmacokinetics and tolerability following 14-day topical application in male AGA patients
NCT01189279	Phase 1	Completed	42	Safety and PK of novel bimatoprost formulations for topical alopecia use — two formulation comparisons
NCT02676310	Phase 1	Terminated	53	Dose-escalation safety/tolerability/PK in male AGA — early termination limits data interpretation
NCT00187577	N/A	Completed	14	Latanoprost vs. bimatoprost ophthalmic solution for eyelash regrowth in alopecia areata — small exploratory study

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40252129	2025	RCT	Archives of Dermatological Research	CO₂ fractional laser + bimatoprost significantly enhances hair regrowth in alopecia areata versus laser alone; confirms adjunctive efficacy
32250713	2022	Systematic Review	Journal of Dermatological Treatment	Network meta-analysis of non-surgical AGA treatments in men and women; bimatoprost included as an emerging comparator
35278027	2022	Prospective Study	Dermatologic Therapy	Topical bimatoprost for eyelash loss in alopecia totalis/universalis: 16 of 19 patients showed measurable response over ~30 weeks
37089845	2023	Prospective Non-Randomized	Indian Dermatology Online Journal	Head-to-head comparison of bimatoprost vs. clobetasol propionate in scalp alopecia areata; bimatoprost shows comparable outcomes
28264599	2017	Review	Expert Opinion on Investigational Drugs	Comprehensive synthesis of bimatoprost evidence across eyelash, eyebrow, and scalp alopecia — key reference for repurposing rationale
29863806	2018	Clinical Guideline	Journal of Dermatology	Japanese 2017 guidelines for male and female pattern hair loss — positions bimatoprost in the treatment landscape
29854658	2018	Review	Indian Dermatology Online Journal	Overview of bimatoprost in dermatology: mechanism, alopecia subtypes, and pigmentation applications
35040730	2022	Experimental	Drug Delivery	Novel topical formulation achieves 4.6× higher skin flux and 529% greater dermal deposition vs. standard preparation — formulation optimization data
37185388	2023	Review	Current Oncology	Chemotherapy-induced alopecia prevention and treatment overview — bimatoprost discussed as topical hair growth promoter
32642317	2020	Review	Dermatology Practical & Conceptual	CIA prevention and treatment review — provides context for bimatoprost’s potential in chemotherapy-related hair loss

Safety Considerations

Please refer to the SmPC for safety information.

Note: TFDA package insert data (warnings, contraindications) and DDI profile are currently unavailable (DG001, DG002). These data gaps are rated Blocking and High severity respectively and must be resolved before entering formal safety evaluation.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 2 RCTs (n = 244–307 per trial) demonstrate bimatoprost’s safety and biological activity in androgenetic alopecia, and Phase 1/2 data in alopecia areata is encouraging; FDA approval of Latisse® for eyelash hypotrichosis provides a regulatory precedent and safety baseline that substantially de-risks topical development.

To proceed, the following is needed:

Resolve DG001: Obtain and parse TFDA package insert PDF to identify key warnings and contraindications
Resolve DG002: Retrieve full MOA documentation from DrugBank API (DB00905)
Conduct DDI profiling (currently zero interactions on record — unknown whether truly absent or data gap)
Assess Taiwan TFDA regulatory pathway: reference to FDA Latisse® NDA and Phase 2 AGA RCT packages
Design or identify a Phase 3 trial for scalp AGA — existing Phase 2 data does not confirm superiority over minoxidil, which is the primary barrier to commercialization
Establish scalp-specific safety monitoring protocol, including ocular adverse event surveillance (iris pigmentation, periocular changes) for topical scalp application
Clarify route compatibility for Taiwan development (topical solution formulation optimization data available — PMID 35040730)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.